Introduction

Biomedical Reports

2049-9434 2049-9442

D.A. Spandidos

BR-16-6-01535

10.3892/br.2022.1535

Articles

Genetic predictions of life expectancy in southern Thai patients with β⁰-thalassemia/Hb E

Nuinoon

Manit

1 2 Rattanaporn

Patchara

3 Benjchareonwong

Thongchai

4 Choowet

Anuchit

5 Suwanno

Komsai

6 Saekoo

Ngamta

6 Lekpetch

Krongjit

7 Thipthara

Orapan

8 Svasti

Saovaros

3 9 Fucharoen

Suthat

1Hematology and Transfusion Science Research Center, Walailak University, Nakhon Si Thammarat 80160, Thailand 2School of Allied Health Sciences, Walailak University, Nakhon Si Thammarat 80160, Thailand 3Thalassemia Research Center, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom 73170, Thailand 4Department of Clinical Pathology and Anatomy, Chumphon Ket-Udomsak Hospital, Chumphon 86000, Thailand 5Department of Pediatrics, Vachira Phuket Hospital, Phuket 83000, Thailand 6Department of Internal Medicine, Hatyai Hospital, Songkhla 90110, Thailand 7Department of Pediatrics, Suratthani Hospital, Suratthani 84000, Thailand 8Department of Pediatrics, Maharaj Nakhon Si Thammarat Hospital, Nakhon Si Thammarat 80000, Thailand 9Department of Biochemistry, Faculty of Science, Mahidol University, Bangkok 10400, Thailand

Correspondence to: Dr Manit Nuinoon, School of Allied Health Sciences, Walailak University, National Highway 401, Nakhon Si Thammarat 80160, Thailand manit.nu@wu.ac.th

Abbreviations: Hb E, hemoglobin E; Hb F, fetal hemoglobin; NBS, newborn screening; PND, prenatal diagnosis; SNPs, single nucleotide polymorphisms

06 2022

06 05 2022

16 6

08 02 2022 20 04 2022

2020

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

The types of β-thalassemia mutations, α-thalassemia interactions, and Hb F-associated SNPs have been described in association with variable disease phenotypes. This study aimed to determine the updated spectrum of β-thalassemia mutations and evaluate the contribution of primary and secondary genetic modifiers and SNPs to disease severity, age at onset, and predicted life expectancy in southern Thai β-thalassemia patients. A total of 181 β-thalassemia patients were enrolled and 135 β⁰-thalassemia/Hb E patients without α-thalassemia interactions were divided into three categories according to disease severity, age at onset, and predicted life expectancy. A total of 16 β-thalassemia mutations were identified in this study, and the three most common β-thalassemia mutations accounted for 61.4% of all mutations. It was also found that the XmnI polymorphism and rs2071348 were associated with age at onset and the predicted life expectancy. More than 82% of β⁰-thalassemia/Hb E patients with CC genotype (XmnI) were 3 years old or younger at onset. Additionally, >90% of the higher predicted life expectancy in β⁰-thalassemia/Hb E patients had the T allele of XmnI. Therefore, genetic prediction for age at onset and life expectancy is beneficial and practical during prenatal diagnosis or newborn screening for better genetic counseling and optimal management.

β-thalassemia mutations disease severity predicted life expectancy genetic modifiers single nucleotide polymorphisms

Funding: This study was funded by a grant from the Thailand Research Fund (grant no. MRG5580069).

Introduction

β-Thalassemia and hemoglobin E (Hb E), two globin gene defects characterized by β-globin gene mutations, lead to reduced (β⁺), absent (β⁰), or abnormal (β^E) β-globin chain synthesis. In Thailand, β-thalassemia and Hb E are very common, with frequencies varying from 3-9 and 10-60%, respectively (1,2). In Southeast Asia, particularly in Thailand, β-thalassemia/Hb E and homozygous β-thalassemia are common β-thalassemia diseases (3). Phenotypic variations in disease severity have been observed in β-thalassemia disease ranging from mild to severe clinical phenotypes (4-6). Clinical presentation of severe cases (β-thalassemia major-like phenotype) occurs between 6 and 24 months (7). Genetic factors affecting unbalanced globin chain synthesis in β-thalassemia disease are primary and secondary genetic modifiers of disease severity such as the type of β-thalassemia mutation (primary modifier) and coinheritance of α-thalassemia and polymorphisms associated with Hb F levels (secondary modifiers) (8-10).

The type of β-thalassemia mutation represents β⁺ or β⁰. In Thailand, in addition to Hb E, the three most common β-thalassemia mutations reported are as follows: Codons 41/42 (-TTCT), codon 17 (A>T) and IVS II-654 (C>T) (3,10). In the southern Thai population, IVS I-5 (G>C), codon 19 (A>G), and Hb Malay were also common after codons 41/42 (-TTCT), which are the most common in all regions of Thailand (11-14). Additionally, genetic variations at three major loci (HBB cluster, HBS1L-MYB, and BCL11A) have been associated with fetal hemoglobin levels and disease phenotypes in β-thalassemia disease (15-17). In Thailand, several SNPs located in the HBB cluster, HBS1L-MYB, and BCL11A have been identified by two genome-wide association studies with different platforms (17,18). Several informative SNPs for predicting disease severity in Thai and Malaysian β⁰-thalassemia/Hb E patients have recently been developed (19). In Thailand, the average life expectancy in β-thalassemia/Hb E patients is ~30 years (20,21). Several genetic and environmental factors as well as the treatment and management of each patient have been associated with life expectancy. Cardiovascular complications are a common cause of death in β-thalassemia major due to iron overload (21,22). According to the current management of patients with safe blood transfusion and iron chelation, the life expectancy in thalassemia major was comparable with that in thalassemia intermedia (23). Therefore, proper management could be considered at the age of presentation (age at onset) of each patient to extend the life expectancy of severe cases. This study aimed to determine the updated spectrum of β-thalassemia mutations to predict the contribution of genetic modifiers to disease severity, age at onset, and predicted life expectancy in southern Thai β-thalassemia patients.

Materials and methods <sec> <title>Ethical statement

Ethical clearance of the study protocol was obtained from the Institutional Review Board of Walailak University (Nakhon Si Thammarat, Thailand; approval no. 12/030). Written informed consent was obtained from all patients/guardians. All experiments were performed in accordance with relevant guidelines and regulations.

Study population

A cross-sectional study was conducted on β-thalassemia patients enrolled from thalassemia clinics, pediatric departments (child patients), and internal medicine departments (adult patients) from 6 different provinces between July 2012 and August 2014. All patients were diagnosed with β-thalassemia/Hb E (Hb types of EF or EFA) or homozygous β-thalassemia (Hb types of A₂F or A₂FA) based on the clinical manifestations, a complete blood count, and hemoglobin analysis. DNA analyses were then performed for confirmation of β-thalassemia/Hb E and homozygous β-thalassemia. Disease severity was classified using a scoring system according to 6 independent parameters as follows: the hemoglobin level at steady state, the age at first blood transfusion, a requirement for blood transfusion, the spleen size (or splenectomy status), the age at disease presentation and growth development (24).

Hematological analysis

A complete blood count was performed using the Sysmex XN-1000 automated hematology analyzer (Sysmex Corporation). Hemoglobin analysis was performed using an automated high-performance liquid chromatography (HPLC-Variant II β-thalassemia short program, Bio-Rad Laboratories, Inc.).

DNA extraction and measurement of the concentration and purity of the extracted genomic DNA

Genomic DNA was extracted from peripheral blood leukocytes using the Genomic DNA Extraction Kit (Geneaid) according to the manufacturer's instructions. The concentration and purity of gDNA were measured at wavelengths of 260 and 280 nm using a Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies; Thermo Fisher Scientific, Inc.).

Characterization of globin gene mutations

β-Thalassemia mutations were characterized using polymerase chain reaction (PCR)-based methods. Common β-globin gene mutations were first identified by PCR-reverse dot blot hybridization (PCR-RDB) (25), all probe sequences are listed in Table SI. or a multiplex amplification refractory mutation system (MARMS) (26) followed by multiplex gap-PCR (deletion type) (14). The Hb E allele was confirmed by real-time PCR-high resolution melting (HRM) analysis as described previously (27). Mutational characterization of DNA samples with negative results from PCR-RDB or MARMS-PCR and other PCR-based methods were further identified by automated DNA sequencing (Solgent Co., Ltd) of the whole HBB gene as described previously (28), the additional forward and reverse primer sequences were 5'-CGGCTGTCATCACTTAGACC-3' and 5'-GCAGCTTGTCACAGTGCAG-3', respectively (product size, 598 bp). Common α-globin gene deletions, including α-thalassemia 1 alleles (--^SEA and --^THAI) and α-thalassemia 2 alleles (-α^3.7 and -α^4.2), were characterized by multiplex gap-PCR whereas Hb constant spring and Hb Pakse alleles were identified by allele-specific PCR as described in previous studies (29,30). All primer sequences are shown in Table SII.

Single nucleotide polymorphism (SNP) genotyping

Four SNPs [rs7482144 (XmnI), rs2071348 (HBBP1) rs766432 and rs9376074] from three representative regions (HBB cluster, BCL11A and HBS1L) were selected for genotyping. PCR-restriction fragment length polymorphism (RFLP) was used to characterize the genotypes of rs7482144, rs2071348 and rs766432 as described previously and the primer sequences for SNP genotyping were as follows: rs7482144 forward primer, 5'-GGCCTAAAACCACAGAGAGT-3' and reverse primer, 5'-CCAGAAGCGAGTGTGTGGAA-3'; rs2071348 forward primer, 5'-GGCACCTTTGCTACACTGAG-3' and reverse primer, 5'-TCATCATTCGGAGGGAAACA-3', and rs766432 forward primer, 5'-AAAATCTCAGAATACAAAGGGC-3' and reverse primer, 5'-GTTAGGGAAGGGGATTGAC-3' (27,31,32). Additionally, SNP genotyping of rs9376074 was performed using PCR-HRM and the primer sequences were: Forward, 5'-GAAGATGAAGCTAAGGTTTGG-3' and reverse, 5'-TCTGACTCCTCAAATGCC-3' (27).

Statistical analysis

Descriptive statistics were used to describe the spectrum of β-globin gene mutations, disease severity score/grouping, and hematological parameters of the patients. Clinical and hematological data from different severities of patients were compared using a χ² test for categorical variables and the Kruskal-Wallis test for continuous variables (non-normally distributed data) between the mild, moderate and severe groups using SPSS (version 26.0. IBM Corp.). Single SNP association analyses for disease severity, age at onset, and predicted life expectancy were performed in the recessive and allelic models using a Pearson's χ² test and/or Fisher's exact test. The P-value, odds ratios (OR), and 95% conference intervals (CIs) were calculated to compare genotype and allele frequencies using 2x2 contingency tables in publicly accessible statistical software (http://vassarstats.net/odds2x2.html). P<0.05 was considered to indicate a statistically significant difference. The clustered bar and the 100% stacked column were constructed using Infogram (https://infogram.com/) and Microsoft Excel, respectively.

Results <sec> <title>Patient classification according to α- and β-globin genotypes and disease phenotypes

A total of 181 β-thalassemia patients were enrolled and classified according to their β-globin genotypes, including 24 homozygous β-thalassemia and 157 β-thalassemia/Hb E patients. Clinical data, physical examination, complete blood count, and hemoglobin analysis were used for evaluating disease phenotypes. In addition, α-thalassemia interactions were found in 4 homozygous β-thalassemia and 9 β-thalassemia/Hb E patients. A total of 135 β⁰-thalassemia/Hb E without α-thalassemia interactions were divided into 3 categories according to their predicted life expectancy, disease severity, and the age of onset. According to an average life expectancy of β⁰-thalassemia/Hb E patients (30 years of age), the 135 β⁰-thalassemia/Hb E patients were divided into two groups according to age: ≤30 (33 patients from severe cases who were predicted to have a lower life expectancy) and >30 (33 patients from all cases who were predicted to have a higher life expectancy). The second category was grouped according to disease severity, including 18 mild cases, 76 moderate cases, and 41 severe cases. The third category was grouped according to age at onset, including 61 cases with an age at onset ≤2 years old and 74 cases with an age at onset >2 years old (a threshold of 2 years of age was selected as this is the cutoff point between thalassemia major and thalassemia intermedia), as shown in Fig. 1.

Disease severity and primary and secondary genetic modifiers in southern Thai β-thalassemia patients

The 181 patients with β-thalassemia were classified as 34 mild cases, 95 moderate cases, and 52 severe cases and further subdivided into 6 groups according to the β-globin genotypes (Table I). Among the 181 patients with β-thalassemia, β⁰-thalassemia/Hb E accounted for 78% and was grouped into 21 mild cases, 80 moderate cases, and 41 severe cases. All β-thalassemia patients with β⁺/β⁺ and β⁺/β^E genotypes were grouped as the mild disease phenotype and demonstrated that the primary modifier, the type of β-globin mutation, can predict disease severity. Additionally, the effect of the secondary genetic modifier, α-thalassemia interaction, was demonstrated as β-thalassemia patients who carry α-thalassemia 2 (-α^3.7/αα); 50% had mildly affected and 50% had moderately affected phenotypes. Moreover, one patient with β-thalassemia who carried Hb CS heterozygote had a mildly affected phenotype. In contrast, homozygous β⁰-thalassemia patients were mostly scored as a severely affected phenotype. A homozygous β⁰-thalassemia patient coinheritance with α-thalassemia 2 heterozygote had a mildly affected phenotype. Rarely did a patient with compound heterozygosity for IVSII-837, T>G (unclear β⁺ or β⁰), and Hb E have a moderate disease phenotype. Among 14 patients (8%), only one β-thalassemia mutation could be identified leaving 14 uncharacterized β-thalassemia alleles.

Clinical and hematological characteristics of southern Thai β0-thalassemia/Hb E patients in different age groups

Several patient characteristics were significantly different between the 2 age groups (≤30 years old and >30 years old), such as age, age at presentation, age at first blood transfusion, frequency of blood transfusion, spleen status, and growth development (P<0.05). Approximately 97% of the ≤30-year-old group required regular blood transfusion. A greater number of splenectomized patients was highly observed in the ≤30-year age group. According to the standard Thai growth chart, the >30-year-old group was found mostly (>73%) in the 10th-25th percentile, whereas in the ≤30 years age group it was mostly observed (>67%) in the 3rd-10th percentile (Table II). Obvious differences in all clinical and hematological findings between the 3 disease severity groups were observed (Table SIII).

An updated β-thalassemia mutational spectrum in southern Thai β-thalassemia patients

In the present study, 181 patients with β-thalassemia including, 24 with homozygous β-thalassemia and 157 with β-thalassemia/Hb E disease, were recruited. In total, 362 β-globin alleles from 181 β-thalassemia patients and 16 different mutations were identified, among which 3 common mutations accounted for 61.4% (Hb E was not included) as follows: Codons 41/42, -TTCT; IVS I-5, G>C and codon 17, A>T with frequencies of 23.9, 23.4, and 14.1%, respectively. All 3 of the most common mutations were categorized as β⁰ (codons 41/42, -TTCT and codon 17, A>T) or the severe form of β⁺ (IVS I-5, G>C). A total of 14 alleles of the β-globin gene, from 14 β-thalassemia patients were not successfully characterized in either allele of the β-globin gene, and these patients were grouped as having uncharacterized β-globin gene mutations (Fig. 2).

Associations between SNPs and disease severity and age at onset

The associations between the 4 SNPs and the disease severity of β⁰-thalassemia/Hb E patients using mild and severe disease severity groups. The XmnI polymorphism showed a strong association with the disease severity (P=0.004; OR, 3.20; 95% CI, 1.42-7.22) (Table SIV). To predict the age at onset of southern Thai β⁰-thalassemia/Hb E patients according to the SNP genotypes from 3 independent regions, the CC genotype of XmnI (rs7482144) was a strong predictor and showed a significantly increased risk for younger age at onset (P=0.004; OR, 3.13; 95% CI, 1.40-7.00). In contrast, there was no association in BCL11A (rs766432) and HBS1L-MYB (rs9376074) regions (Table SV). Among the 3 genotypes of XmnI, the mean and standard deviation of age at onset (2.5±3.19, 6.6±9.39, and 20.6±24.59 years) were increased according to the number of T alleles (CC, CT, and TT, respectively). In addition, the comparisons of the mean age at onset from each genotype were significant (P<0.05) (Fig. 3A). To apply the XmnI genotypes for predicting the age at onset, the TT genotype was observed in >90% of individuals in the >2 years of age group, and the CC genotype was observed in >60% of the individuals in the ≤2 years of age group. The frequency of the TT genotype in the >2 years of age group was higher than that in the ≤2 years of age group (P=0.0006; OR, 21.08; 95% CI, 2.42-183.34) (Fig. 3B).

Associations between SNPs and the predicted life expectancy

The associations between the 4 candidate SNPs from 3 independent regions and the predicted life expectancy of β⁰-thalassemia/Hb E patients were next assessed. The XmnI (rs7482144) polymorphism showed a strong association with the predicted life expectancy (P=0.004; OR, 6.50; 95% CI, 1.64-25.80). The CT or TT genotype of XmnI was associated with a higher predicted lifespan than those with the CC genotype. In addition, rs2071348 also exhibited an association with the predicted life expectancy (P=0.016). In contrast, rs766432 and rs9376074 demonstrated no association with the predicted life expectancy (P=0.458 and 0.438, respectively) (Table III).

Cascade genetic testing of β0-thalassemia/Hb E patients for phenotype predictions

According to the overall results, the age at onset, predicted life expectancy, and disease severity were assigned as phenotypic variations in β-thalassemia patients. Phenotypic variations were then classified into 2 groups: Low or high predicted life expectancy. The genotyping of β-thalassemia mutations, α-thalassemia interactions, and XmnI genotypes were sequentially recommended for phenotype prediction; for example, the CT or TT genotype of XmnI was observed in 90.9% of β⁰-thalassemia/Hb E patients with high predicted life expectancy (Fig. 4).

Discussion

β-thalassemia and Hb E are very common in Thailand, in which the frequency of the β-thalassemia trait varies from 3 to 9%, and the frequency of Hb E is 13% on average and varies from region to region. The frequency of Hb E is very high at the junction of Thailand, Laos, and Cambodia at 50-60% (33). In Thailand, the number of patients with compound heterozygotes for β-thalassemia and Hb E is higher than that for homozygous β-thalassemia because the frequency of Hb E is much higher than that for β-thalassemia (3,20,34). β-thalassemia/Hb E disease showed diverse disease phenotypes ranging from mild to severely affected patients (6,21). The variation in disease severity in β-thalassemia patients could be explained by β-thalassemia mutations (10), α-thalassemia interactions (35,36), and genetic determinants of Hb F production (15,17,18,37,38), and other factors related to the pathophysiology of β-thalassemia (39-41). Several genetic modifiers associated with disease severity and fetal hemoglobin levels in β-thalassemia/Hb E patients have been well studied in the Thai population (10,17,18). Factors affecting life expectancy in β-thalassemia patients were a subset of disease severity-associated genetic factors and proper treatments such as safe blood transfusion, iron chelation, and other supportive therapies can decrease disease complications. However, there is no report of SNP frequency data and some rare β-thalassemia mutations in southern Thai β⁰-thalassemia/Hb E patients. According to different genetic backgrounds and migration, the mutational spectrum of β-thalassemia and SNP frequency in southern Thai differed in other parts of Thailand. This phenomenon has also been observed in various countries such as India (42-44), Malaysia, China (45,46), and other countries (47). Therefore, the predictive performance of the β-thalassemia mutations and SNPs would differ in each region in the same country.

According to the primary modifier, the present study demonstrated that all β⁺/β⁺ and β⁺/β^E patients were scored as mildly affected due to the primary modifier (10,17). The frequency of disease severity among β⁰/β^E southern Thai patients with mild, moderate, and severe disease phenotypes was distributed in a different pattern than in previous studies because of the different genetic backgrounds (17,24) of the studied patients. This study revealed that the β-thalassemia mutations are very heterogeneous, with a wider distribution in southern Thailand than in other parts of Thailand. The 3 most common β-thalassemia mutations in this study were 61.4%, which differed from the central (72.4%), northern (83.1%), and northeastern (80.3%) regions of Thailand (12). A total of 17 β-thalassemia mutations, including Hb E, were identified in 181 southern Thai β-thalassemia patients in the present study. Comparing these results to previously published reports in the southern Thai population, the 4 most common mutations, codons 41/42 (-TTCT), IVS I-5 (G>C), codon 17 (A>T), and codon 19 (A>G) accounted for 67.7% of mutations in the present study and revealed slightly different patterns and frequencies due to the differences in the collected sample backgrounds, such as ethnicity (11), thalassemia status (trait or disease) (48), different provinces (12-14) of southern Thailand and migration (47) (Fig. S1). Although this study recruited patients from several provinces of southern Thailand, a similar pattern of the most common β-thalassemia mutations was observed. The origin of patients may explain the difference in distribution; for example, codons 41/42 (-TTCT) are very common in individuals of Chinese origin (45,46), whereas IVS I-5 (G>C) is very common in the Malay (49) and Asian Indian (50) populations. Interestingly, the present study demonstrated comparable frequencies of codons 41/42; -TTCT (23.9%) and IVS I-5; G>C (23.4%) because of the higher sample size of Thai-Muslim patients. The spectrum and frequency of β-thalassemia mutations in the southern Thai population were different from those in other regions of Thailand (3,51). Hb Malay was found at the highest frequency (11.7%) in the southern region of Thailand compared with other parts of Thailand (12,13). The frequency of Hb Malay in our study was 6.3%, ranking as the fourth most common β-thalassemia mutation in southern Thailand. Heterozygous β-thalassemia (IVS II-837; T>G) was first described in Asian Indians with unclear β⁺ or β⁰ thalassemia showing a typical asymptomatic carrier, and the incidence of this mutation was found in the Gaud Saraswat (44), Brahmins in Goa, and Karnataka (52) states of southern India. Phenotypes of the homozygous state of IVS II-837 (T>G) were transfusion-dependent (52). Interestingly, compound heterozygotes of IVS II-837 (T>G) and Hb E were found for the first time in the present study and showed a moderately affected phenotype with regular blood transfusion. According to the disease phenotype from this study and previous reports, IVS II-837 (T>G) could be categorized as β⁺-thalassemia (severe form) (44,52).

Coinheritance of α-thalassemia in β-thalassemia patients is one of the ameliorating factors due to more balanced globin chain synthesis (35,36). Heterozygous α-thalassemia 2 and Hb CS were found only in 7 mild and 6 moderate cases in the present study. The α-thalassemia 1 allele was not detected in our β-thalassemia patients. A possible reason is that the coinheritance of α-thalassemia 1 leads to mild β-thalassemia; thus, these patients were not found in a hospital-based sample collection (35). Furthermore, several genetic markers in the HBB cluster (10,15,17,51), BCL11A (15,17,19), and HBS1L-MYB (15,17) have been associated with fetal hemoglobin and disease severity in several populations. In addition, mutations in human Krüppel-like factor 1 (KLF1) were found to be associated with increased fetal hemoglobin (Hb F) and hemoglobin A₂ (Hb A₂) (53,54). KLF1 mutations have been studied in patients with β-thalassemia/Hb E, and a higher Hb F level was observed in the cases with KLF1 mutations (38,51).

According to hospital-based sample collection, the present study failed to enroll sufficient mild cases (n=18) for SNP analysis in disease severity because the mild case has a lower frequency of going to the hospital. However, XmnI and rs2071348 were associated with disease severity in β⁰-thalassemia/Hb E (with low power). The T allele frequency of XmnI in mild cases (0.611) was significantly higher than that in severe cases (0.329). No associations were found in rs766432 and rs9376074 because of the low sample size in mild cases (Table SIV). An increased sample size could improve the statistical power in all SNPs due to the similar trend of the allele frequencies (17).

Currently, the life expectancy between thalassemia major and thalassemia intermedia is comparable due to the use of safe blood transfusions, effective iron chelation, and improved management of cardiovascular complications (23,55). Proper patient management should be initiated during the age at onset for improved quality of life and increased life expectancy. Therefore, the prediction of the age at onset is important not only for patient management in newborns but also for genetic counseling in prenatal diagnosis (PND). Our study showed the association between SNPs and the age at onset and the predicted life expectancy of southern Thai β⁰-thalassemia/Hb E patients. Interestingly, the XmnI polymorphism and rs2071348 were associated with the age at onset and the predicted life expectancy. The XmnI polymorphism is the strongest marker for predicting the age at onset and the predicted life expectancy in southern Thai patients with β⁰-thalassemia/Hb E. This polymorphism is well identified in association with fetal hemoglobin levels and disease phenotypes in different groups of populations (10,15,17-19,51). Due to the improved and individualized management of the patients, an improved life expectancy and quality of life were observed in β-thalassemia patients. In addition, the life expectancy of thalassemia major patients was similar to that of thalassemia intermedia patients (23,55,56). Therefore, the genetic prediction of age at onset and life expectancy is suggested for better patient management after newborn screening. Concerning precision medicine, the β-thalassemia mutations and XmnI (rs7482144) polymorphism could be simultaneously genotyped to improve genetic counseling in PND. However, this suggested guideline should be validated on a national scale and with considerably larger sample sizes in the future.

In summary, genetic heterogeneity and a broad spectrum of β-globin gene mutations were observed in southern Thai β-thalassemia patients. This study provides an updated spectrum of β-thalassemia mutations. Hb Malay, IVS I-5 (G>C), 105-bp deletion, and 3.5-kb deletion were primarily found in the southern Thai population, accounting for 34.1% of all mutations. The type of β-globin gene mutation and co-inheritance of α-thalassemia are strong predictors of disease severity. The XmnI polymorphism and rs2071348 were associated with the age at onset and predicted life expectancy. However, SNPs on BCL11A and intergenic HBS1L-MYB are required to confirm the genetic association in a larger sample size. This study demonstrates that the XmnI polymorphism is the best genetic predictor for age at onset and life expectancy. Therefore, genetic prediction for age at onset and life expectancy may be beneficial and practical during PND or newborn screening for better genetic counseling and optimal management.

Supplementary Material

Comparison of the frequencies (%) of β-thalassemia mutations in southern Thailand.

List of amino-linked oligonucleotide probes for PCR-reverse dot blot hybridization with common and rare β-thalassemia mutations (<xref rid="b25-BR-16-6-01535" ref-type="bibr">25</xref>).

List of primer sequences of PCR-RDB, MARMS-PCR, multiplex-gap PCR, PCR-HRM, and DNA sequencing.

Clinical and hematological findings of the 135 southern Thai β0-thalassemia/Hb E patients without α-thalassemia interactions.

Association of 4 SNPs in 3 independent regions with disease severity in southern Thai β0-thalassemia/Hb E patients without α-thalassemia interactions.

Association of 4 SNPs in 3 independent regions with the age at onset in 135 southern Thai β0-thalassemia/Hb E patients without α-thalassemia interactions.

Acknowledgements

We would like to thank Mrs. Dararat Horpet for the technical support and all of the patients who participated in this research project.

Availability of data and materials

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

Authors' contributions

MN designed and performed the experiments, analyzed the data, and wrote the manuscript. PR performed PCR-HRM. TB, AC, KS, NS, KL, and OT provided clinical data and performed the physical examination and helped in obtaining blood specimens. SS and SF provided DNA controls and helped to design the experiments. All authors have read and approved the final manuscript. MN, TB, AC, KS, NS, KL, and OT confirm the authenticity of all the raw data.

Ethics approval and consent to participate

The study was conducted according to the Declaration of Helsinki guidelines and approved by the Human Research Ethics Committee of Walailak University (Nakhon Si Thammarat, Thailand; approval no. 12/030).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References 1

Fucharoen

Winichagoon

Siritanaratkul

Chowthaworn

Pootrakul

α- and β-thalassemia in Thailand

Ann N Y Acad Sci8504124141998

9668570

10.1111/j.1749-6632.1998.tb10507.x

Fucharoen

Winichagoon

Hemoglobinopathies in Southeast Asia: Molecular biology and clinical medicine

Hemoglobin212993191997

9255610

10.3109/03630269709000664

Thein

Winichagoon

Hesketh

Best

Fucharoen

Wasi

Weatherall

The molecular basis of β-thalassemia in Thailand: Application to prenatal diagnosis

Am J Hum Genet473693751990

2393018

Winichagoon

Thonglairoam

Fucharoen

Wilairat

Fukumaki

Wasi

Severity differences in β-thalassaemia/haemoglobin E syndromes: Implication of genetic factors

Br J Haematol836336391993

7686036

10.1111/j.1365-2141.1993.tb04702.x

Fucharoen

Winichagoon

Pootrakul

Piankijagum

Wasi

Variable severity of Southeast Asian β⁰-thalassemia/Hb E disease

Birth Defects Orig Artic Ser232412481987

3689905

Fucharoen

Ketvichit

Pootrakul

Siritanaratkul

Piankijagum

Wasi

Clinical manifestation of β-thalassemia/hemoglobin E disease

J Pediatr Hematol Oncol225525572000

11132229

10.1097/00043426-200011000-00022

Galanello

Origa

β-thalassemia

Orphanet J Rare Dis5112010

20492708

10.1186/1750-1172-5-11

Nuntakarn

Fucharoen

Sanchaisuriya

Jetsrisuparb

Wiangnon

Molecular, hematological and clinical aspects of thalassemia major and thalassemia intermedia associated with Hb E-β-thalassemia in Northeast Thailand

Blood Cells Mol Dis4232352009

18951049

10.1016/j.bcmd.2008.09.002

Yamsri

Singha

Prajantasen

Taweenan

Fucharoen

Sanchaisuriya

Fucharoen

A large cohort of β⁽⁺⁾-thalassemia in Thailand: Molecular, hematological and diagnostic considerations

Blood Cells Mol Dis541641692015

25471338

10.1016/j.bcmd.2014.11.008

Winichagoon

Fucharoen

Chen

Wasi

Genetic factors affecting clinical severity in β-thalassemia syndromes

J Pediatr Hematol Oncol225735802000

11132233

10.1097/00043426-200011000-00026

Laosombat

Nopparatana

Wongchanchailert

Wiriyasateinkul

Molecular basis of β-thalassemia in Thai Muslim patients in the the south of Thailand

Southeast Asian J Trop Med Public Health28 (Suppl 3)S104S1051997

9640609

Laosombat

Fucharoen

Panich

Fucharoen

Wongchanchailert

Sriroongrueng

Nopparatana

Kenpitak

Maipang

Fukumaki

Molecular basis of β-thalassemia in the South of Thailand

Am J Hematol411941981992

1415194

10.1002/ajh.2830410310

Laosombat

Wongchanchailert

Sattayesevana

Nopparatana

Clinical, hematological and molecular features in Thais with β-Malay/β-thalassemia and β-Malay/HbE

Southeast Asian J Trop Med Public Health28 (Suppl 3)S106S1091997

9640610

Nopparatana

Panich

Saechan

Sriroongrueng

Nopparatana

Rungjeadpha

Pornpatkul

Laosombat

Fukumaki

The spectrum of β-thalassemia mutations in Southern Thailand

Southeast Asian J Trop Med Public Health26 (Suppl 1)S229S2341995

8629112

Lettre

Sankaran

Bezerra

Araújo

Uda

Sanna

Cao

Schlessinger

Costa

Hirschhorn

Orkin

DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease

Proc Natl Acad Sci USA10511869118742008

18667698

10.1073/pnas.0804799105

Abel

Sripichai

Whitacre

Angkachatchai

Makarasara

Winichagoon

Fucharoen

Braun

Farrer

β-globin gene cluster polymorphisms are strongly associated with severity of HbE/β⁽⁰⁾-thalassemia

Clin Genet724975052007

17894837

10.1111/j.1399-0004.2007.00897.x

Nuinoon

Makarasara

Mushiroda

Setianingsih

Wahidiyat

Sripichai

Kumasaka

Takahashi

Svasti

Munkongdee

A genome-wide association identified the common genetic variants influence disease severity in β⁰-thalassemia/hemoglobin E

Hum Genet1273033142010

20183929

10.1007/s00439-009-0770-2

Sherva

Sripichai

Abel

Whitacre

Angkachatchai

Makarasara

Winichagoon

Svasti

Fucharoen

Genetic modifiers of Hb E/β⁰-thalassemia identified by a two-stage genome-wide association study

BMC Med Genet11512010

20353593

10.1186/1471-2350-11-51

Munkongdee

Tongsima

Ngamphiw

Wangkumhang

Peerapittayamongkol

Hashim

Fucharoen

Svasti

Predictive SNPs for β⁰-thalassemia/HbE disease severity

Sci Rep11103522021

33990643

10.1038/s41598-021-89641-2

Fucharoen

Weatherall

The hemoglobin E thalassemias

Cold Spring Harb Perspect Med2a0117342012

22908199

10.1101/cshperspect.a011734

Fucharoen

Winichagoon

Clinical and hematologic aspects of hemoglobin E β-thalassemia

Curr Opin Hematol71061122000

10698297

10.1097/00062752-200003000-00006

Cunningham

Macklin

Neufeld

Cohen

Thalassemia Clinical Research Network

Complications of β-thalassemia major in North America

Blood10434392004

14988152

10.1182/blood-2003-09-3167

Vitrano

Calvaruso

Lai

Colletta

Quota

Gerardi

Concetta Rigoli

Pitrolo

Cuccia

Gagliardotto

The era of comparable life expectancy between τhalassaemia major and intermedia: Is it time to revisit the major-intermedia dichotomy?

Br J Haematol1761241302017

27748513

10.1111/bjh.14381

Sripichai

Makarasara

Munkongdee

Kumkhaek

Nuchprayoon

Chuansumrit

Chuncharunee

Chantrakoon

Boonmongkol

Winichagoon

Fucharoen

A scoring system for the classification of β-thalassemia/Hb E disease severity

Am J Hematol834824842008

18186524

10.1002/ajh.21130

Winichagoon

Saechan

Sripanich

Nopparatana

Kanokpongsakdi

Maggio

Fucharoen

Prenatal diagnosis of β-thalassaemia by reverse dot-blot hybridization

Prenat Diagn194284351999

10360511

Mirasena

Shimbhu

Sanguansermsri

Detection of β-thalassemia mutations using a multiplex amplification refractory mutation system assay

Hemoglobin324034092008

18654891

10.1080/03630260701798391

Kesornsit

Jeenduang

Horpet

Plyduang

Nuinoon

Quantitative trait loci influencing Hb F Levels in Southern Thai Hb E (HBB: c.79G>A) Heterozygotes

Hemoglobin4223292018

29457528

10.1080/03630269.2018.1429281

Nuinoon

Jeenduang

Kesornsit

Horpet

Plyduang

Hematological and molecular characterization of a novel Hb A₂ variant with homozygous α-thalassemia-2 in a Southern Thai Individual

Hemoglobin412132152017

28795619

10.1080/03630269.2017.1345760

Chong

Boehm

Higgs

Cutting

Single-tube multiplex-PCR screen for common deletional determinants of α-thalassemia

Blood953603622000

10607725

Fucharoen

Sanchaisuriya

Fucharoen

Panyasai

Devenish

Luy

Interaction of hemoglobin E and several forms of α-thalassemia in Cambodian families

Haematologica88109210982003

14555303

Fucharoen

Shimizu

Fukumaki

A novel C-T transition within the distal CCAAT motif of the ^Gγ-globin gene in the Japanese HPFH: Implication of factor binding in elevated fetal globin expression

Nucleic Acids Res18524552531990

1698280

10.1093/nar/18.17.5245

Roy

Bhattacharya

Mandal

Dasgupta

Banerjee

Chandra

Das

Influence of BCL11A, HBS1L-MYB, HBBP1 single nucleotide polymorphisms and the HBG2 XmnI polymorphism On Hb F levels

Hemoglobin365925992012

23094636

10.3109/03630269.2012.735626

Fucharoen

Winichagoon

Haemoglobinopathies in Southeast Asia

Indian J Med Res1344985062011

22089614

Yamsri

Sanchaisuriya

Fucharoen

Sae-Ung

Ratanasiri

Fucharoen

Prevention of severe thalassemia in Northeast Thailand: 16 years of experience at a single university center

Prenat Diagn305405462010

20509153

10.1002/pd.2514

Winichagoon

Fucharoen

Weatherall

Wasi

Concomitant inheritance of α-thalassemia in β⁰-thalassemia/Hb E disease

Am J Hematol202172221985

2998183

10.1002/ajh.2830200303

Sripichai

Munkongdee

Kumkhaek

Svasti

Winichagoon

Fucharoen

Coinheritance of the different copy numbers of α-globin gene modifies severity of β-thalassemia/Hb E disease

Ann Hematol873753792008

18026953

10.1007/s00277-007-0407-2

Jomoui

Tepakhan

Yamsri

Srivorakun

Fucharoen

A novel SNP rs11759328 on Rho GTPase-activating protein 18 gene is associated with the expression of Hb F in hemoglobin E-related disorders

Ann Hematol9923292020

31776727

10.1007/s00277-019-03862-0

Khamphikham

Sripichai

Munkongdee

Fucharoen

Tongsima

Smith

Genetic variation of Krüppel-like factor 1 (KLF1) and fetal hemoglobin (HbF) levels in β⁰-thalassemia/HbE disease

Int J Hematol1072973102018

29067594

10.1007/s12185-017-2357-3

Azman

Abdullah

Hanafi

Diana

Bahar

Johan

Zilfalil

Hassan

Genetic polymorphisms of HbE/β-thalassemia related to clinical presentation: Implications for clinical diversity

Ann Hematol997297352020

32078010

10.1007/s00277-020-03927-5

Zarghamian

Azarkeivan

Arabkhazaeli

Mardani

Shahabi

Hepcidin gene polymorphisms and iron overload in β-thalassemia major patients refractory to iron chelating therapy

BMC Med Genet21752020

32268883

10.1186/s12881-020-01011-3

Torres

Bernardo

Silva

DGH

Okumura

Bonini-Domingos

Association of FOXO3 polymorphism (rs3800231) and clinical subphenotypes of β-thalassemic individuals. Hematol Transfus Cell Ther: Nov 22, 2020 (Epub ahead of print).

Kumar

Kaur

Agarwal

Influence of Xmn 1^(G)γ (HBG2 c.-211 C → T) globin gene polymorphism on phenotype of Thalassemia patients of North India

Indian J Hematol Blood Transfus302862902014

25435729

10.1007/s12288-013-0293-9

Bandyopadhyay

Roychowdhury

Chandra

Das

Dasgupta

Variable severity of β-thalassemia patients of Eastern India: Effect of α-thalassemia and XmnI polymorphism

Clin Exp Med11551592001

11833853

10.1007/s10238-001-8028-x

Colah

Gorakshakar

Control of thalassemia in India

Thalass Rep419552014

Zhuang

Zhang

Wang

Zhang

Zheng

Jiang

Xie

Chen

Molecular characterization analysis of thalassemia and hemoglobinopathy in Quanzhou, Southeast China: A large-scale retrospective study

Front Genet127272332021

34659349

10.3389/fgene.2021.727233

Yin

Luo

Zhang

Chen

Gao

Liang

The prevalence and molecular spectrum of α- and β-globin gene mutations in 14,332 families of Guangdong Province, China

PLoS One9e898552014

24587075

10.1371/journal.pone.0089855

Kattamis

Forni

Aydinok

Viprakasit

Changing patterns in the epidemiology of β-thalassemia

Eur J Haematol1056927032020

32886826

10.1111/ejh.13512

Nopparatana

Saechan

Karnchanaopas

Srewaradachpisal

Prenatal diagnosis of α- and β-thalassemias in southern Thailand

Int J Hematol1112842922020

31659625

10.1007/s12185-019-02761-4

Abdullah

UYH

Ibrahim

Mahmud

Salleh

The

Noorizhab

MNFB

Zilfalil

Jassim

Wilairat

Fucharoen

Genotype-phenotype correlation of β-thalassemia in Malaysian population: Toward effective genetic counseling

Hemoglobin441841892020

32586164

10.1080/03630269.2020.1781652

Sinha

Black

Agarwal

Colah

Das

Ryan

Bellgard

Bittles

Profiling β-thalassaemia mutations in India at state and regional levels: Implications for genetic education, screening and counselling programmes

Hugo J351622009

21119755

10.1007/s11568-010-9132-3

Yamsri

Pakdee

Fucharoen

Sanchaisuriya

Fucharoen

Molecular Understanding of Non-Transfusion-Dependent Thalassemia Associated with hemoglobin E-β-Thalassemia in Northeast Thailand

Acta Haematol1362332392016

27710960

10.1159/000449120

Bashyam

Chaudhary

Bhat

The IVS-II-837 (T>G) Appears to be a Relatively Common ‘Rare’ β-Globin Gene Mutation in β-Thalassemia patients in Karnataka State, South India

Hemoglobin364975032012

22734501

10.3109/03630269.2012.700532

Liu

Zhang

Cai

Zheng

Zhou

Liu

Wei

Lin

KLF1 mutations are relatively more common in a thalassemia endemic region and ameliorate the severity of β-thalassemia

Blood1248038112014

24829204

10.1182/blood-2014-03-561779

Perseu

Satta

Moi

Demartis

Manunza

Sollaino

Barella

Cao

Galanello

KLF1 gene mutations cause borderline HbA₂

Blood118445444582011

21821711

10.1182/blood-2011-04-345736

Borgna-Pignatti

Rugolotto

De Stefano

Zhao

Cappellini

Del Vecchio

Romeo

Forni

Gamberini

Ghilardi

Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine

Haematologica89118711932004

15477202

Taher

Bou-Fakhredin

Kattamis

Viprakasit

Cappellini

Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: Recommendations for best clinical practice and the use of novel treatment strategies

Expert Rev Hematol148979092021

34493145

10.1080/17474086.2021.1977116

Figure 1

Schematic flow of patient enrollment and classification according to β-globin genotypes, α-thalassemia interactions, age at onset, disease severity and predicted life expectancy. β^?, uncharacterized β-globin gene mutation; CBC, complete blood count; Hb, hemoglobin.

Figure 2

Clustered bar of frequency of β-globin gene mutations among 181 southern Thai β-thalassemia patients.

Figure 3

Genotype-phenotype correlation. (A) Box plot displaying the age at onset with the three different genotypes of rs7482144 (XmnI). (B) Stacked bar chart of the percentage of patients by age at onset (cutoff at 2 years of age) according to the 3 different genotypes. OR, odds ratio; SD, standard deviation.

Figure 4

Genetic prediction pipeline for phenotype of β-thalassemia. β⁺, reduced β-globin chain synthesis; β⁰, absent β-globin chain synthesis; α^CSα, Hb Constant Spring allele; SNP, single nucleotide polymorphism; -α^3.7, 3.7 kb rightward deletion.

Table I

Primary (β-thalassemia mutations) and secondary modifiers (α-thalassemia mutations) of disease severity in the southern Thai β-thalassemia cohort.

	Disease severity (score range)
β-globin gene genotype	Mild (0.0-3.5)	Moderate (4.0-7.0)	Severe (7.5-10.0)	Total, n
β⁺/β⁺ or β⁺/β^E
nt -28, A>G/nt -28, A>G	2	0	0	2
nt -28, A>G/Codon 19, A>G	1 [1]^b	0	0	1
nt -28, A>G/Codon 26, G>A (Hb E)	4 [1]^a	0	0	4
Total, n (%)	7 (100%)	0 (0%)	0 (0%)	7
β⁰ (or β⁺severe form)/β⁺
3.5-kb HBB deletion/Codon 19, A>G	0	1	0	1
Codons 41/42, -TTCT/Codon 19, A>G	1 [1]^a	2	2	5
Codon 17, A>T/Codon 19, A>G	0	0	2	2
IVS I-1, G>T/Codon 19, A>G	0	0	1	1
IVS II-654, C>T/Codon 19, A>G	0	1	1	2
Total, n (%)	1 (9%)	4 (36%)	6 (55%)	11
β⁰ (or β⁺severe form)/β^E
Codons 8/9, +G/Hb E	0	2	0	2
Codon 17, A>T/Hb E	1	14	8	23
IVS I-1, G>T/Hb E	4	5	2	11
IVS I-5, G>C/Hb E	5 [1]^a	26 [1]^a	15	46
Codon 35, C>A/Hb E	0	1	1	2
Codon 41 (-C), TTC>TT-/Hb E	1 [1]^a	2	1	4
Codons 41/42, -TTCT/Hb E	5	22 [3]^a	12	39
Codon 43, G>T/Hb E	0	1	0	1
Codons 71/72, +A/Hb E	1 [1]^a	0	0	1
IVS II-654, C>T/Hb E	1	4	2	7
105-bp HBB deletion/Hb E	0	2	0	2
3.5-kb HBB deletion/Hb E	3	1	0	4
Total, n (%)	21 (15%)	80 (56%)	41 (29%)	142
β⁰ (or β⁺severe form)/β⁰
Codon 17, A>T/Codon 17, A>T	0	0	1	1
Codon 17, A>T/IVS I-1, G>T	0	0	1	1
Codon 17, A>T/Codons 41/42, -TTCT	0	0	1	1
Codons 41/42, -TTCT/Codons 41/42, -TTCT	0	1	1	2
IVS I-5, G>C/3.5-kb HBB deletion	1 [1]^a	0	0	1
Total, n (%)	1 (17%)	1 (17%)	4 (66%)	6
β^{+ or 0}/β^E (rare type, unclear β⁺ or β⁰)
IVS II-837, T>G/Hb E	0	1	0	1
Total, n (%)	0 (0%)	1 (100%)	0 (0%)	1
β^Unch/β^E, β^Unch/β⁰ and β^Unch/β⁺
Uncharacterized mutation/Hb E	3	7 [1]^a	0	10
Uncharacterized mutation/105 bp HBB deletion	0	1 [1]^a	0	1
Uncharacterized mutation/IVS I-5, G>C	0	1	0	1
Uncharacterized mutation/Codon 15, -T	0	0	1	1
Uncharacterized mutation/Codon 19, A>G	1	0	0	1
Total, n (%)	4 (29%)	9 (64%)	1 (7%)	14
β⁺-Thalassemia (2 alleles), n (%)	7 (100%)	0 (0%)	0 (0%)	7
α-Thalassemia interaction/Hb CS, n (%)	7 (54%)	6 (46%)	0 (0%)	13
Total β-thalassemia patients, n (%)	34 (19%)	95 (52%)	52 (29%)	181

^aHeterozygous α-thalassemia 2 (-α^3.7/αα) was observed in 6 mild cases and 6 moderate cases.

^bHeterozygous Hb CS (α^CSα/αα) was characterized in 1 mild case. Numbers in square brackets [] represent the number of samples with heterozygous α-thalassemia 2 or heterozygous Hb CS. bp, base pair; Hb, hemoglobin; HBB, β-globin gene; Hb CS, Hb Constant Spring; IVS, intervening sequence; kb, kilobase; nt, nucleotide; Unch, uncharacterized.

Table II

Baseline, clinical, and hematological profiles of 66 southern Thai β⁰-thalassemia/Hb E patients without α-thalassemia interactions categorized by age groups.

	Age group
Patient characteristics	≤30-year-old, severe cases, n=33	>30-year-old, all cases, n=33	P-value
Sex, n (%)			0.210^d
Male	11(33)	16(48)
Female	22(67)	17(52)
Age (years), mean ± SD	14.1±4.73	46.2±12.63	<0.0001^c,e
Baseline Hb (g/dl), mean ± SD	6.7±0.99	6.9±1.32	0.705^e
Age at presentation (years), mean ± SD	1.4±0.93	18.6±18.15	<0.0001^c,e
Age at first transfusion (years), mean ± SD	1.8±1.48	22.8±19.94	<0.0001^c,e
Requirement for regular blood transfusion, n (%)	32(97)	19(58)	0.0001^c,d
Spleen size (cm), mean ± SD	7.2±4.80	7.1±5.52	0.966^e
Splenectomy, n (%)	23(70)	12(36)	0.007^a,d
Growth development: Height, n (%)			0.0003^b,d
≤P3-10	23(70)	8(25)
≥P10-25	10(30)	24(75)
Growth development: Weight, n (%)			0.0013^a,d
≤P3-10	22(67)	9(27)
≥P10-25	11(33)	24(73)

^aP≤0.01,

^bP≤0.001,

^cP≤0.0001.

^dχ² test.

^eMann-Whitney U test. P, percentile.

Table III

Association of the 4 SNPs in 3 independent regions with the predicted life expectancy in southern Thai β⁰-thalassemia/Hb E patients without α-thalassemia interactions.

		Age Range Status
SNP info	Genotype/allele	≤30-year-old, severe cases, n=33	>30-year-old, all cases, n=33	P-value^b	Odds ratio (95% Confidence interval)	Risk Genotype/Allele^a
rs7482144 (C/T), HBG2
Genotype	CC	13 (0.394)	3 (0.091)	0.004	6.50 (1.64-25.80)	CC
	CT+TT	20 (0.606)	30 (0.909)
Allele	C	46 (0.697)	29 (0.440)	0.003	2.93 (1.43-6.00)	C
	T	20 (0.303)	37 (0.560)
rs2071348 (A/C), HBBP1
Genotype	AA	11 (0.333)	3 (0.091)	0.016	5.00 (1.24-20.08)	AA
	AC+CC	22 (0.667)	30 (0.909)
Allele	A	43 (0.652)	28 (0.424)	0.009	2.54 (1.26-5.13)	A
	C	23 (0.348)	38 (0.576)
rs766432 (C/A), BCL11A
Genotype	AA	20 (0.606)	17 (0.515)	0.458	1.45 (0.54-3.84)	AA
	AC+CC	13 (0.394)	16 (0.485)
Allele	A	53 (0.803)	49 (0.742)	0.406	1.41 (0.62-3.21)	A
	C	13 (0.197)	17 (0.258)
rs9376074 (T/C), HBS1L
Genotype	TT	13 (0.394)	10 (0.303)	0.438	1.50 (0.54-4.14)	TT
	TC+CC	20 (0.606)	23 (0.697)
Allele	T	42 (0.636)	37 (0.561)	0.374	1.37 (0.68-2.76)	T
	C	24 (0.364)	29 (0.439)

^aRisk genotypes/alleles were set as reference genotypes/alleles and the recessive model was used to analyze the case-control association study.

^bAt age ≤30 years (case group) vs. at age >30 years (control group) were analyzed. SNP; single nucleotide polymorphism.